Profile
Thomas P.
Mcdonnell worked as Vice President-US Marketing at Shire Plc from 2013 to 2015 and as Chief Commercial Officer at Neos Therapeutics, Inc. from 2015 to 2018.
He completed his undergraduate degree from Muhlenberg College.
Former positions of Thomas P. Mcdonnell
Companies | Position | End |
---|---|---|
NEOS THERAPEUTICS, INC. | Corporate Officer/Principal | 2018-11-28 |
SHIRE | Corporate Officer/Principal | 2015-02-28 |
Training of Thomas P. Mcdonnell
Muhlenberg College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Neos Therapeutics, Inc.
Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
- Stock Market
- Insiders
- Thomas P. Mcdonnell